Experimental therapies. gene therapies and oncolytic viruses.

M. Maher Hulou, Choi Fong Cho, E. Antonio Chiocca*, Rolf Bjerkvig

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

21 Citations (Scopus)


Glioblastoma is the most common and aggressive primary brain tumor in adults. Over the past three decades, the overall survival time has only improved by a few months, therefore novel alternative treatment modalities are needed to improve clinical management strategies. Such strategies should ultimately extend patient survival. At present, the extensive insight into the molecular biology of gliomas, as well as into genetic engineering techniques, has led to better decision processes when it comes to modifying the genome to accommodate suicide genes, cytokine genes, and tumor suppressor genes that may kill cancer cells, and boost the host defensive immune system against neoantigenic cytoplasmic and nuclear targets. Both nonreplicative viral vectors and replicating oncolytic viruses have been developed for brain cancer treatment. Stem cells, microRNAs, nanoparticles, and viruses have also been designed. These have been armed with transgenes or peptides, and have been used both in laboratory-based experiments as well as in clinical trials, with the aim of improving selective killing of malignant glioma cells while sparing normal brain tissue. This chapter reviews the current status of gene therapies for malignant gliomas and highlights the most promising viral and cell-based strategies under development.

Original languageEnglish
Title of host publicationGliomas, 2016
EditorsMitchel S. Berger, Michael Weller
Number of pages15
ISBN (Print)9780128029978
Publication statusPublished - 2016

Publication series

NameHandbook of Clinical Neurology
ISSN (Print)0072-9752
ISSN (Electronic)2212-4152


  • Gene therapy
  • Glioblastoma
  • Malignant glioma
  • MicroRNA
  • Nanoparticle
  • Oncolytic virus
  • Stem cell


Dive into the research topics of 'Experimental therapies. gene therapies and oncolytic viruses.'. Together they form a unique fingerprint.

Cite this